Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Relapsed or Refractory AL Amyloidosis
NCT06569147Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2024
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in amyloid light chain amyloidosis, sponsored by Dana-Farber Cancer Institute. Started Nov 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06569147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569147.